Noxopharm Limited
ASX: NOX.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shawn Van Boheemen
- Headquarters
- Chatswood, Australia
- IPO year
- 2016
- Market cap
- A$21.5M
- Website
- https://www.noxopharm.com
Loading NOX…
Loading profile data…Frequently asked questions about NOX
What does Noxopharm Limited (NOX.AX) do?
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program...
Where does NOX.AX trade?
Noxopharm Limited (NOX.AX) trades on the Australian Securities Exchange.
What sector is NOX.AX in?
Noxopharm Limited (NOX.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Noxopharm Limited?
Shawn Van Boheemen is the chief executive officer of Noxopharm Limited (NOX.AX).
Where is Noxopharm Limited headquartered?
Noxopharm Limited is headquartered in Australia.
Does NOX.AX pay a dividend?
Noxopharm Limited (NOX.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NOX.AX go public?
Noxopharm Limited (NOX.AX) completed its initial public offering in 2016.